Egypt's Vaccine City to Attract $240 Million in Investments by 2030, Positioning Country as Regional Biotech Hub
Key Insights
Egypt's Vaccine City and Biotechnology project (search) in Ismailia Governorate is expected to attract EGP 12 billion (approximately $240 million) in investments by 2030, according to Health Minister Khaled Abdel Ghaffar.
The facility features three production lines with a combined annual capacity of 140 million vaccine doses and includes 9,000 square metres of specialized cold-storage infrastructure.
The project adopts a "One Health" approach, combining human and veterinary vaccine production at a single site to address zoonotic diseases, and is expected to create approximately 1,500 jobs.
Egypt's ambitious Vaccine City and Biotechnology project (search) is projected to attract investments totaling EGP 12 billion — approximately $240 million — by 2030, marking a significant milestone in the country's drive toward pharmaceutical self-sufficiency and regional healthcare leadership. The announcement was made by Minister of Health and Population Khaled Abdel Ghaffar during a visit to the facility in Ismailia Governorate.
The minister described the initiative as "a matter of national security" and a launching point for establishing Egypt as a regional hub for vaccine production serving Africa and the Middle East. The project is structured as a model of partnership between the government, Egyptian investors, and international partners, reflecting Egypt's broader strategy to strengthen sustainable health security and localize biotechnology industries.
Production Capacity and Infrastructure
The Vaccine City facility houses three production lines with a combined annual capacity of 140 million vaccine doses. During the ministerial visit, delegates toured the city's training academy, central filling facilities, and specialized cold-storage facilities covering an area of 9,000 square metres. The site also includes utility buildings, power and water treatment stations, and an integrated cold-chain network with advanced storage systems that meet international standards.
Abdel Ghaffar emphasized that these capabilities help maintain a strategic vaccine stockpile and strengthen preparedness for epidemics and health emergencies.
One Health Approach and Sustainability
A distinguishing feature of the project is its adoption of a "One Health" approach, combining the production of human and veterinary vaccines at a single site to address diseases transmitted between humans and animals. The facility also relies on solar and other clean energy sources as part of its environmental sustainability strategy.
Economic and Workforce Impact
The project is expected to create approximately 1,500 jobs for trained Egyptian professionals and will be supported by a specialized academy dedicated to capacity building, aligning with the objectives of Egypt Vision 2030. Abdel Ghaffar stressed that achieving greater self-sufficiency in vaccine production would help reduce import costs and ease pressure on foreign currency demand, while enhancing Egypt's healthcare resilience.
Ismailia Governor Nabil Hasballah described the project as "an exceptional national achievement" and evidence of Egypt's ability to build an advanced technological and research base in the biotechnology sector.
Strategic Implementation
Vaccine City Chief Executive Officer Magdy El-Sayed reviewed the project's expansion plans and implementation progress during the visit, emphasizing the importance of coordination among all stakeholders to achieve its strategic objectives. The project forms part of Egypt's broader efforts to localize strategic industries, enhance pharmaceutical and biotechnology manufacturing capabilities, and strengthen the country's position as a regional centre for healthcare innovation and vaccine production.